FATE Stock Forecast: Fate Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Fate Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 18 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Fate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (79): Sales and profits are climbing, and climbing faster than before.
Volatility (26): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FATE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FATE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $3.50 → $3.00 |
| 27 Oct 2026 | Wedbush | Reiterates | Outperform | $7.00 |
| 14 Aug 2026 | Piper Sandler | Reiterates | Overweight | $6.00 → $8.00 |
| 14 Aug 2026 | Wedbush | Reiterates | Outperform | $7.00 |
| 14 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $2.50 → $3.50 |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Oct 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 27 Oct 2025 | Needham | Reiterates | Hold | — |
| 27 Oct 2025 | Wedbush | Upgrade | Outperform | — |
| 13 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 June 2025 | Needham | Reiterates | Hold | — |
| 14 May 2025 | Baird | Maintains | Neutral | — |
| 14 May 2025 | Barclays | Maintains | Overweight | — |
| 14 May 2025 | Needham | Reiterates | Hold | — |
| 6 Mar 2025 | Needham | Reiterates | Hold | — |
| 6 Mar 2025 | Stifel | Maintains | Hold | — |
| 6 Mar 2025 | Wedbush | Reiterates | Neutral | — |
| 6 Mar 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 19 Nov 2024 | Needham | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FATE.
This page is one stock. Monday covers all of them.
FATE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FATE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Fate Therapeutics, Inc. returned −3.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FATE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 26.1×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 7% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −67.8%
- Return on assets
- −27.9%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fate Therapeutics, Inc. has a market value of $124.1M and an enterprise value of $59.4M.
Revenue in the twelve months to 30 June 2026: $6.5M. The latest quarter grew 9.2% year on year.
Net income over the same four quarters: −$126.0M, a −1941.1% net margin.
Diluted earnings per share, trailing twelve months: −$1.05.
Free cash flow in the twelve months to 30 June 2026: −$105.7M.
Fate Therapeutics, Inc. employs 161 people — $40K of revenue per employee.
Data provided by Twelve Data
FATE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FATE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Fate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FATE
What is the FATE stock price forecast for 2026-2027?
The median 12-month analyst price target for Fate Therapeutics, Inc. is $7, with estimates ranging from $2.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FATE stock a buy right now?
Of the 11 analysts covering Fate Therapeutics, Inc., 5 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fate Therapeutics, Inc. 85 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FATE?
As at 18 Nov 2026, Fate Therapeutics, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
Will FATE stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts is $7, and Ticker Nerd's factor model ranks Fate Therapeutics, Inc. 85 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FATE stock forecast for 2030?
No analyst covering Fate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FATE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $8 over the next 12 months.
How has FATE stock performed over the past year?
Fate Therapeutics, Inc. returned -3.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Fate Therapeutics, Inc. do?
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing.
About Fate Therapeutics, Inc.
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.
CEO Dr. Bahram Valamehr M.B.A., Ph.D. · 161 employees · United States · https://www.fatetherapeutics.com